CryoPort (NASDAQ:CYRX) Shares Up 5.9% – Still a Buy?

CryoPort, Inc. (NASDAQ:CYRX)’s stock price shot up 5.9% during mid-day trading on Tuesday . The company traded as high as $10.04 and last traded at $10.12. 154,122 shares traded hands during trading, a decline of 73% from the average session volume of 572,803 shares. The stock had previously closed at $9.56.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. Weiss Ratings reiterated a “sell (d)” rating on shares of CryoPort in a research report on Monday, November 24th. BTIG Research increased their target price on shares of CryoPort from $10.00 to $15.00 and gave the company a “buy” rating in a research note on Thursday, September 18th. Needham & Company LLC raised their target price on shares of CryoPort from $11.00 to $12.00 and gave the stock a “buy” rating in a report on Wednesday, November 5th. Finally, UBS Group upped their price target on CryoPort from $11.00 to $12.50 and gave the company a “buy” rating in a report on Wednesday, November 5th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $12.83.

CryoPort Price Performance

The company has a debt-to-equity ratio of 0.40, a current ratio of 15.77 and a quick ratio of 15.01. The firm has a market cap of $499.19 million, a price-to-earnings ratio of 8.53 and a beta of 1.51. The stock’s fifty day moving average price is $9.40 and its 200-day moving average price is $8.41.

CryoPort (NASDAQ:CYRX) last posted its quarterly earnings data on Tuesday, November 4th. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.05. CryoPort had a net margin of 35.57% and a negative return on equity of 11.07%. The firm had revenue of $44.23 million during the quarter, compared to analyst estimates of $41.22 million. Equities research analysts predict that CryoPort, Inc. will post -0.99 EPS for the current fiscal year.

Insider Buying and Selling at CryoPort

In related news, Director Robert J. Hariri sold 25,000 shares of the company’s stock in a transaction on Thursday, September 11th. The stock was sold at an average price of $9.71, for a total transaction of $242,750.00. Following the transaction, the director directly owned 51,275 shares of the company’s stock, valued at approximately $497,880.25. The trade was a 32.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 10.10% of the company’s stock.

Hedge Funds Weigh In On CryoPort

Several institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. lifted its position in shares of CryoPort by 2.5% in the third quarter. Vanguard Group Inc. now owns 2,858,031 shares of the company’s stock worth $27,094,000 after purchasing an additional 69,550 shares in the last quarter. Millennium Management LLC increased its stake in CryoPort by 18.5% in the 3rd quarter. Millennium Management LLC now owns 2,620,906 shares of the company’s stock valued at $24,846,000 after buying an additional 408,335 shares during the period. Thematics Asset Management increased its stake in CryoPort by 12.8% in the 2nd quarter. Thematics Asset Management now owns 1,914,885 shares of the company’s stock valued at $14,285,000 after buying an additional 216,937 shares during the period. Assenagon Asset Management S.A. lifted its position in CryoPort by 37.4% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,498,774 shares of the company’s stock worth $14,208,000 after buying an additional 408,263 shares in the last quarter. Finally, UBS Group AG boosted its stake in shares of CryoPort by 112.7% during the 3rd quarter. UBS Group AG now owns 1,331,521 shares of the company’s stock valued at $12,623,000 after buying an additional 705,649 shares during the period. Hedge funds and other institutional investors own 92.90% of the company’s stock.

CryoPort Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.